Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: A study by the Consortium for Improving Survival of Lymphoma

Consortium for Improving Survival of Lymphoma (CISL) study group

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.

Original languageEnglish
Pages (from-to)1020-1026
Number of pages7
JournalLeukemia and Lymphoma
Volume56
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Lymphoma
Drug Therapy
Survival
Recurrence
Radiotherapy
Central Nervous System
Rituximab

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{92f3078dca274b61be9d95bc77faacb7,
title = "Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: A study by the Consortium for Improving Survival of Lymphoma",
abstract = "Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8{\%}) patients received R-CHOP chemotherapy alone, whereas 21 (26.3{\%}) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8{\%}), whereas central nervous system (CNS) relapse was observed in only one (1.9{\%}) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.",
author = "{Consortium for Improving Survival of Lymphoma (CISL) study group} and Lee, {Gyeong Won} and Go, {Se Il} and Kim, {Seok Hyun} and Junshik Hong and Kim, {Yu Ri} and Sukjoong Oh and Kim, {Sung Yong} and Do, {Young Rok} and Hyewon Lee and Lee, {Soon Il} and Bae, {Sung Hwa} and Oh, {Sung Yong} and Song, {Moo Kon} and Lee, {Won Sik} and Bohee Lee and Jinseok Kim and Kim, {Min Kyoung} and Kang, {Hye Jin} and Ahn, {Jae Sook} and Yhim, {Ho Young} and Kim, {Hyo Jung} and Kim, {Seok Jin} and Kim, {Won Seog} and Cheolwon Suh",
year = "2015",
month = "4",
day = "1",
doi = "10.3109/10428194.2014.946027",
language = "English",
volume = "56",
pages = "1020--1026",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy

T2 - A study by the Consortium for Improving Survival of Lymphoma

AU - Consortium for Improving Survival of Lymphoma (CISL) study group

AU - Lee, Gyeong Won

AU - Go, Se Il

AU - Kim, Seok Hyun

AU - Hong, Junshik

AU - Kim, Yu Ri

AU - Oh, Sukjoong

AU - Kim, Sung Yong

AU - Do, Young Rok

AU - Lee, Hyewon

AU - Lee, Soon Il

AU - Bae, Sung Hwa

AU - Oh, Sung Yong

AU - Song, Moo Kon

AU - Lee, Won Sik

AU - Lee, Bohee

AU - Kim, Jinseok

AU - Kim, Min Kyoung

AU - Kang, Hye Jin

AU - Ahn, Jae Sook

AU - Yhim, Ho Young

AU - Kim, Hyo Jung

AU - Kim, Seok Jin

AU - Kim, Won Seog

AU - Suh, Cheolwon

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.

AB - Abstract We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions. A total of 59 (73.8%) patients received R-CHOP chemotherapy alone, whereas 21 (26.3%) were treated with R-CHOP followed by involved field radiotherapy (IFRT). In 73 patients with Ann Arbor stage I-II disease, no significant difference was found in the response rate or overall survival (OS) between R-CHOP alone (n = 52) and R-CHOP followed by IFRT (n = 21). Among 11 relapsed patients in this study, the most common pattern of relapse was local (n = 8, 11.8%), whereas central nervous system (CNS) relapse was observed in only one (1.9%) patient. These results suggest that patients with primary SN-DLBCL treated with R-CHOP have a relatively low CNS relapse rate and better OS compared to previous studies before the introduction of R.

UR - http://www.scopus.com/inward/record.url?scp=84929077148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929077148&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.946027

DO - 10.3109/10428194.2014.946027

M3 - Article

C2 - 25039351

AN - SCOPUS:84929077148

VL - 56

SP - 1020

EP - 1026

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -